Teva Pharma Company Insiders
TEVA Stock | USD 16.10 0.14 0.86% |
Teva Pharma employs about 33.9 K people. The company is managed by 38 executives with a total tenure of roughly 180 years, averaging almost 4.0 years of service per executive, having 891.89 employees per reported executive. Analysis of Teva Pharma's management performance can provide insight into the company performance.
Kaare Schultz CEO President, Chief Executive Officer, Director |
Amir Elstein Chairman Vice Chairman of the Board |
Teva |
Teva Pharma Management Team Effectiveness
The company has return on total asset (ROA) of 0.0509 % which means that it generated a profit of $0.0509 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.283) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Teva Pharma Workforce Comparison
Teva Pharma Industries is rated second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 186,669. Teva Pharma retains roughly 33,892 in number of employees claiming about 18% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.21 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.21. Teva Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Teva Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Teva Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Teva Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amir Weiss over a week ago Disposition of 3566 shares by Amir Weiss of Teva Pharma subject to Rule 16b-3 | ||
Richard Francis over a month ago Disposition of 161655 shares by Richard Francis of Teva Pharma subject to Rule 16b-3 | ||
Eliyahu Kalif over a month ago Acquisition by Eliyahu Kalif of 183169 shares of Teva Pharma subject to Rule 16b-3 | ||
Lichtenstein Chen over three months ago Insider Trading | ||
Shalev Varda over six months ago Disposition of 12872 shares by Shalev Varda of Teva Pharma subject to Rule 16b-3 | ||
Hughes Eric A over six months ago Disposition of 45060 shares by Hughes Eric A of Teva Pharma at 17.3762 subject to Rule 16b-3 | ||
Sol Barer over six months ago Disposition of 37598 shares by Sol Barer of Teva Pharma subject to Rule 16b-3 | ||
Mark Sabag over six months ago Disposition of 100000 shares by Mark Sabag of Teva Pharma at 13.5209 subject to Rule 16b-3 |
Teva Pharma Notable Stakeholders
A Teva Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Teva Pharma often face trade-offs trying to please all of them. Teva Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Teva Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Richard Francis | CEO President | Profile | |
Kaare Schultz | President, Chief Executive Officer, Director | Profile | |
Amir Elstein | Vice Chairman of the Board | Profile | |
Sol Barer | Independent Chairman of the Board | Profile | |
Richard Daniell | Executive Vice President - European Commercial | Profile | |
Mark Sabag | Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | Profile | |
Gianfranco Nazzi | Executive Vice President - International Markets Commercial | Profile | |
Brendan OGrady | Executive Vice President - North America Commercial | Profile | |
Hafrun Fridriksdottir | Executive Vice President and Presidentident of Global Generics R&D | Profile | |
Eliyahu Kalif | Chief Financial Officer, Executive Vice President | Profile | |
Kathleen Veit | Global President | Profile | |
David Stark | Executive Vice President, Chief Legal Officer | Profile | |
Sven Dethlefs | Executive Vice President - Global Marketing & Portfolio and International Markets Commercial | Profile | |
Nechemia Peres | Independent Director | Profile | |
JeanMichel Halfon | Statutory - independent director | Profile | |
Perry Nisen | Independent Director | Profile | |
Gerald Lieberman | Independent Director | Profile | |
Roberto Mignone | Independent Director | Profile | |
Rosemary Crane | Independent Director | Profile | |
Kevin Mannix | Head of Global Investor Relations and VP | Profile | |
Matthew Shields | Executive Operations | Profile | |
Ronit SatchiFainaro | Independent Director | Profile | |
Kare Schultz | CEO Pres | Profile | |
Janet Vergis | Independent Director | Profile | |
Amir Weiss | Senior Vice President Chief Accounting Officer | Profile | |
Christopher CFA | Senior Intelligence | Profile | |
Galia Inbar | Executive Vice President - Global Communications, Brand and ESG, Chief Human Resource Officer | Profile | |
Eli Shani | Executive Vice President - Global Marketing and Portfolio | Profile | |
Abbas Hussain | Independent Director | Profile | |
Eric Drape | Executive Vice President - Global Operations | Profile | |
Vikki Conway | Acting Resources | Profile | |
Advocate Baron | Senior Auditor | Profile | |
Ran Meir | Head Relations | Profile | |
David JD | Executive Officer | Profile | |
Placid Jover | Executive CHRO | Profile | |
Tal Zaks | Independent Director | Profile | |
Andrew Weil | Chief Accounting Officer | Profile | |
Dov Bergwerk | Acting Secretary | Profile |
About Teva Pharma Management Performance
The success or failure of an entity such as Teva Pharma Industries often depends on how effective the management is. Teva Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Teva management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Teva management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel. Teva Pharmaceutical is traded on New York Stock Exchange in the United States.
Please note, the presentation of Teva Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Teva Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Teva Pharma's management manipulating its earnings.
Teva Pharma Workforce Analysis
Traditionally, organizations such as Teva Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Teva Pharma within its industry.Teva Pharma Manpower Efficiency
Return on Teva Pharma Manpower
Revenue Per Employee | 488.1K | |
Revenue Per Executive | 435.4M | |
Net Loss Per Employee | 57.8K | |
Net Loss Per Executive | 51.6M |
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Global Correlations Find global opportunities by holding instruments from different markets |